Literature DB >> 20399690

Expression of Toll-like receptors 7, 8, and 9 in primary Sjögren's syndrome.

Lingyan Zheng1, Zhiyuan Zhang, Chuangqi Yu, Chi Yang.   

Abstract

OBJECTIVE: The objective of this study was to investigate the level of Toll-like receptors (TLRs) 7, 8, and 9 in peripheral mononuclear blood cells (PMBCs) from patients with primary Sjögren's syndrome (pSS) and whether TLR7 and 9 exist in the parotid glands of pSS patients.
METHODS: TLR7, 8, and 9 mRNA levels in PMBC from 37 pSS patients and 24 controls were determined using real-time polymerase chain reaction. TLR7- and TLR9-positive cells in parotid glands from 20 pSS patients and 10 controls were observed using immunofluorescence and immunohistochemistry, respectively. Statistical analysis was performed by Student t test.
RESULTS: TLR7 and TLR9 mRNA levels were 2.17- and 2.33-fold higher in pSS patients than control subjects, respectively (P < .05), whereas TLR8 levels were not. TLR7- and TLR9-positive cells of the pSS group were localized in the epithelial islands, lymphocytes, and ductal epithelial cells of the parotid glands and were more abundant than the TLR7- and TLR9-positive cells that were only localized to the ductal epithelial cells of parotid glands (P < .05).
CONCLUSION: TLR7 and TLR9 mRNA levels are up-regulated in the PMBC of pSS patients, and TLR7- and TLR9-positive cells exist in the epithelial islands, lymphocytes, and ductal epithelial cells of the parotid glands of individuals affected by pSS, but are limited to the ductal epithelial cells of controls. Copyright 2010 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20399690     DOI: 10.1016/j.tripleo.2010.01.006

Source DB:  PubMed          Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol Endod        ISSN: 1079-2104


  27 in total

1.  Dry eye modulates the expression of toll-like receptors on the ocular surface.

Authors:  Rachel L Redfern; Stefano Barabino; Jessica Baxter; Carolina Lema; Alison M McDermott
Journal:  Exp Eye Res       Date:  2015-03-25       Impact factor: 3.467

Review 2.  Toll-like receptors as therapeutic targets for autoimmune connective tissue diseases.

Authors:  Jing Li; Xiaohui Wang; Fengchun Zhang; Hang Yin
Journal:  Pharmacol Ther       Date:  2013-03-24       Impact factor: 12.310

Review 3.  Treatment of primary Sjögren syndrome.

Authors:  Alain Saraux; Jacques-Olivier Pers; Valérie Devauchelle-Pensec
Journal:  Nat Rev Rheumatol       Date:  2016-07-14       Impact factor: 20.543

Review 4.  Toll-Like Receptor Pathways in Autoimmune Diseases.

Authors:  Ji-Qing Chen; Peter Szodoray; Margit Zeher
Journal:  Clin Rev Allergy Immunol       Date:  2016-02       Impact factor: 8.667

5.  Human TLR8 is activated upon recognition of Borrelia burgdorferi RNA in the phagosome of human monocytes.

Authors:  Jorge L Cervantes; Carson J La Vake; Bennett Weinerman; Stephanie Luu; Caitlin O'Connell; Paulo H Verardi; Juan C Salazar
Journal:  J Leukoc Biol       Date:  2013-08-01       Impact factor: 4.962

Review 6.  Advances in understanding the pathogenesis of primary Sjögren's syndrome.

Authors:  Gaëtane Nocturne; Xavier Mariette
Journal:  Nat Rev Rheumatol       Date:  2013-07-16       Impact factor: 20.543

Review 7.  Innate immunity in Sjögren's syndrome.

Authors:  Jeremy Kiripolsky; Liam G McCabe; Jill M Kramer
Journal:  Clin Immunol       Date:  2017-04-08       Impact factor: 3.969

8.  Activation of Toll-like receptor 7 signaling in labial salivary glands of primary Sjögren's syndrome patients.

Authors:  T Shimizu; H Nakamura; A Takatani; M Umeda; Y Horai; S Kurushima; T Michitsuji; Y Nakashima; A Kawakami
Journal:  Clin Exp Immunol       Date:  2018-11-28       Impact factor: 4.330

Review 9.  Uncovering the molecular networks in periodontitis.

Authors:  Fábio Trindade; Frank G Oppenheim; Eva J Helmerhorst; Francisco Amado; Pedro S Gomes; Rui Vitorino
Journal:  Proteomics Clin Appl       Date:  2014-07-14       Impact factor: 3.494

Review 10.  TLR8: the forgotten relative revindicated.

Authors:  Jorge L Cervantes; Bennett Weinerman; Chaitali Basole; Juan C Salazar
Journal:  Cell Mol Immunol       Date:  2012-10-22       Impact factor: 11.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.